Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic HER2-Positive Breast Cancer
Interventions: DRUG: Gemcitabine|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Genentech, Inc.|Hoffmann-La Roche|Hartford HealthCare